Table 1.

Adherence to quality measures stratified by patient and market characteristics. Quality measures: (1) proportion of patients seen by both a urologist and a radiation oncologist between diagnosis and start of treatment (“pretx counseling”), (2) proportion of patients with low-risk cancer avoiding receipt of a non-indicated bone scan (“bone scan”), (3) proportion of patients with high-risk cancer receiving adjuvant androgen deprivation therapy while undergoing radiotherapy (“adjuvant ADT”), (4) proportion of patients treated by a high volume provider (“high-volume provider”), (5a) proportion of patients having at least two follow-up visits with a treating radiation oncologist (“f/u with radonc”), (5b) proportion of patients having at least two follow-up visits with a treating urologist (“f/u with urologist”). Abbreviations: nr: not reported because of low numbers (<100) in the denominator; na: not applicable.

Characteristics	N	% of patients receiving care adherent to quality measure
		(1) pretx counseling	(2) bone scan	(3) adjuvant ADT	(4) high-volume provider	(5a) f/u with radonc	(5b) f/u with urologist
Overall	46,274	53.2	67.5	75.5	32.1	55.0	64.0
Patient characteristics
Age, years
66–69	15,842	42.7^*	69.6^*	71.1^*	32.1	57.8^*	62.9
70–74	16,838	53.9^*	67.1^*	74.1^*	32.5	56.2^*	65.6
75–79	9,916	64.0^*	66.1^*	77.3^*	31.7	53.6^*	66.5
80–84	3,140	66.8^*	57.0^*	80.3^*	31.6	48.2^*	nr
85+	538	62.3^*	nr	83.5^*	30.6	45.0^*	nr
Race/ethnicity
White	38,428	53.6	68.2^**	75.3	32.4^**	55.2	63.4
Black	4,374	52.1	63.6^**	74.6	29.9^**	55.8	68.7
Hispanic	848	49.1	62.7^**	84.2	24.9^**	51.6	69.6
Asian	1,226	50.5	68.8^**	77.1	33.9^**	53.1	67.4
Other/unknown	1,398	51.6	60.5^**	75.9	34.3^**	50.0	64.6
Comorbidity
0	30,711	51.5^*	68.8^*	75.0	32.6^*	55.2	63.2
1	10,369	55.6^*	65.1^*	75.7	31.3^*	56.1	66.2
2	3,246	57.5^*	64.8^*	76.4	31.1^*	52.6	68.4
3+	1,948	60.2^*	62.7^*	78.5	29.6^*	51.3	64.3
D’Amico risk
Low	12,585	54.9^*	67.5	na	35.1^*	59.2^*	63.4
Intermediate	16,484	51.6^*	na	na	33.2^*	54.7^*	62.9
High	12,266	57.2^*	na	75.5	28.4^*	50.8^*	64.6
Year of diagnosis
2004	7,812	52.1	67.5	77.4	33.0	56.3	67.9
2005	7,519	53.3	67.4	72.4	28.6	55.0	65.6
2006	8,148	53.5	66.2	76.1	32.6	55.8	63.0
2007	8,398	52.8	66.1	76.5	35.4	54.4	59.2
2008	7,466	52.1	69.0	74.8	33.0	54.6	64.0
2009	6,931	55.7	70.1	75.8	29.4	52.8	65.1
Socioeconomic status²⁵
Low	13,377	50.4^*	64.2^*	75.6	27.3^*	53.5^*	66.2
Medium	15,331	54.8^*	68.8^*	76.1	31.7^*	54.4^*	63.5
High	16,477	54.1^*	68.9^*	75.0	36.2^*	56.7^*	62.9
Residing in urban area
non-urban	3,831	53.9	62.7^*	76.4	18.8^*	46.5^*	60.9
urban	42,434	53.2	68.0^*	75.4	33.3^*	55.8^*	64.3
Market characteristics
Urologists per 100,000
Low (≤ 53)	14,893	53.3	70.2^*	76.6	29.6^*	53.7^*	63.0
Intermediate	13,994	53.0	68.1^*	75.1	31.0^*	54.0^*	65.2
High (≥ 87)	17,378	53.3	64.8^*	74.9	35.1^*	57.0^*	63.7
Radiation oncologists per 100,000
Low (≤ 22)	15,228	53.4	68.2	76.1	33.2	53.8^*	62.3^*
Intermediate	14,640	54.9	66.9	75.3	29.9	53.7^*	63.4^*
High (≥ 37)	16,397	51.6	67.5	75.2	33.0	57.4^*	65.8^*
Hospital beds per 100,000
Low (≤ 4,735)	14,638	53.9^*	70.9^*	76.6	31.1	52.8^*	63.4
Intermediate	15,566	56.4^*	66.0^*	75.7	35.7	56.6^*	62.5
High (≥ 6,854)	16,061	49.5^*	66.0^*	74.3	29.6	55.5^*	65.6
Medicare Managed Care penetration
Low (≤ 5.1%)	15,319	57.6^*	67.7^*	76.3	25.9^*	53.9	62.9
Intermediate	15,469	54.9^*	62.2^*	76.3	40.3^*	57.9	65.0
High (≥ 17.9%)	15,477	47.2^*	73.4^*	74.0	30.0^*	52.8	64.1
Technological capacity for robotic prostatectomy
Low	11,103	53.7^*	64.9	80.8^*	29.0^*	52.9	62.5
Intermediate	18,097	55.8^*	70.1	72.2^*	33.9^*	57.2	62.9
High	17,074	50.2^*	66.3	75.4^*	32.2^*	53.9	65.6
Technological capacity for IMRT
Low	13,665	46.4^*	69.9^*	76.4	34.9^*	53.8^*	63.5
Intermediate	17,656	54.0^*	69.4^*	71.7	29.6^*	53.3^*	63.0
High	14,953	58.5^*	63.1^*	79.3	32.6^*	58.0^*	65.9

p≤0.001, Mantel-Haenszel chi square test;

^**

p≤0.001, chi square test